Costin, Octavia; Grigorescu-Sido^1, Paula; Cret, Victoria
December 2009
Clujul Medical;Dec2009, Vol. 82 Issue 4, p562
Academic Journal
The presence of dyslipoproteinemia in children and adolescents with type 1 diabetes mellitus represents a major risk to macrovascular complications, which constitutes the main cause of morbidity and mortality of these patients in adulthood. Objective. Our objective was to identify the presence of lipid and lipoprotein abnormalities in these patients and the relationship between glycemic control and dyslipoproteinemia. Material and method. Material was represented by 53 children with type 1 diabetes mellitus. Methods: clinical examination, measurement of plasma cholesterol, triglycerides, HDL cholesterol, apolipoprotein B100, lipoperoxides and glycated haemoglobin (HbA1c). Results. High plasma lipid levels were presented in 15,09% of cases and a positive association between plasma cholesterol, LDL cholesterol and HbA1c was found. The patients also had significantly elevated apolipoprotein B100 levels in 39,47% of cases and increased lipoperoxide levels in 27,77% of cases, regardless of glycemic control. Conclusions. The presence of dyslipoproteinemia in children and adolescents with type 1 diabetes is directly related to glycemic control and is dominated by qualitative changes, that is an important aspect to appreciate the atherogenic risk.


Related Articles

  • Removal from the plasma of the free and esterified forms of cholesterol and transfer of lipids to HDL in type 2 diabetes mellitus patients. Oliveira, Carolina P.; Maranh�o, Raul C.; Bertato, Marina P.; Wajchenberg, Bernardo L.; Lerario, Antonio C. // Lipids in Health & Disease;2012, Vol. 11 Issue 1, p65 

    Background: The aim was to investigate new markers for type 2 diabetes (T2DM) dyslipidemia related with LDL and HDL metabolism. Removal from plasma of free and esterified cholesterol transported in LDL and the transfer of lipids to HDL are important aspects of the lipoprotein intravascular...

  • Combined Therapy in Dyslipidemia and Hyperglicemia of Diabetes Mellitus Type II. Sulaiman, Azhar S.; Zaki, Nada F.; Gillani, Wasif S. // Clinical Medicine Insights: Therapeutics;2010, Issue 2, p789 

    Today the world is facing a high prevalence of dyslipidemia among type II diabetes, and in matter of fact clinical practices against hyperglycemic and hyperlipidemia were quiet intrusive. Our aim was to determine the therapeutic compliance against the clinical practices of dyslipidemia with type...

  • New Therapies Targeting apoB Metabolism for High-Risk Patients with Inherited Dyslipidaemias: What Can the Clinician Expect? Sahebkar, Amirhossein; Watts, Gerald F. // Cardiovascular Drugs & Therapy;Dec2013, Vol. 27 Issue 6, p559 

    Apolipoprotein B (apoB) has a key role in the assembly and secretion of very low-density lipoprotein (VLDL) from the liver. Plasma apoB concentration affects the number of circulating atherogenic particles, and serves as an independent predictor of the risk of atherosclerotic cardiovascular...

  • Association Between Apo Lipoprotein B Levels at Admission of Patients and Short-term Morbidity and Mortality After Myocardial Infarction. Sokhanvar, Sepideh; Khoshi, Amirhossein; Hajiaghaei, Sanaz; Mousavinasab, S. Nouraddin; Golmohammadi, Zahra // Journal of Cardiovascular & Thoracic Research;2012, Vol. 4 Issue 3, p61 

    Introduction: Dyslipidemia is an important risk factor in cardiovascular diseases. Different studies have shown that Apolipoprotein B (Apo B) is one of the best predictors in determining cardiovascular diseases and patients follow up after cardiovascular events. We hypothesized that there is a...

  • The Role and Impact of Research Agendas on the Comparative-Effectiveness Research Among Antihyperlipidemics. Dunn, A G; Bourgeois, F T; Murthy, S; Mandl, K D; Day, R O; Coiera, E // Clinical Pharmacology & Therapeutics;Apr2012, Vol. 91 Issue 4, p685 

    Although it is well established that funding source influences the publication of clinical trials, relatively little is known about how funding influences trial design. We examined a public trial registry to determine how funding source shapes trial design among trials involving...

  • TREATMENT FOR DIABETES MELLITUS WITH HYPERLIPIDEMIA DISEASE AT MINTOHARDJO HOSPITAL. Selawa, Widya; Eff, Aprilita Rinayanti; Rahmatillah, Diana Laila // Wood Industry / Drvna Industrija;2015 Supplement1, Vol. 6 Issue 1, p1968 

    Diabetes mellitusis a metabolic disorder characterized by hyperglycemia associated with abnormalities in the metabolism of carbohydrates, fats, and proteins, caused by a decrease in insulin secretion or a decrease in insulin sensitivity, or both, and it can lead to chronic complications of...

  • THE EFFECT OF GLYCEMIC CONTROL ON SERUM LIPIDS AND CALCIUM - PHOSPHATE PROFILES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS. Abdel-Gayoum, Abdel-Gayoum A.; Musa, Abdalla S. // Egyptian Journal of Biochemistry & Molecular Biology;Jun2009, Vol. 27 Issue 1, p79 

    The present study was carried out to investigate the effect of glycemic control levels in type 2 diabetic patients on the serum lipids and lipoprotein profiles and the serum levels of calcium, phosphate and some other electrolytes. The study was conducted on 81 patients with type 2 diabetes...

  • Epidemiological Survey of Dyslipidemia in Civil Aviators in China from 2006 to 2011. Rongfu Zhao; Dan Xiao; Xiaoying Fan; Zesong Ge; Linsheng Wang; Tiecheng Yan; Jianzhi Wang; Qixin Wei; Yan Zhao // International Journal of Endocrinology;2014, p1 

    Aim. This study aimed to analyze blood lipid levels, temporal trend, and age distribution of dyslipidemia in civil aviators in China. Methods. The 305 Chinese aviators were selected randomly and followed up from 2006 to 2011. Their total cholesterol (TC), triglyceride (TG), high-density...

  • Using Genetic Variants to Assess the Relationship Between Circulating Lipids and Type 2 Diabetes. Fall, Tove; Weijia Xie; Poon, Wenny; Yaghootkar, Hanieh; Mägi, Reedik; Knowles, Joshua W.; Lyssenko, Valeriya; Weedon, Michael; Frayling, Timothy M.; Ingelsson, Erik // Diabetes;Jul2015, Vol. 64 Issue 7, p2676 

    The effects of dyslipidemia on the risk of type 2 diabetes (T2D) and related traits are not clear. We used regression models and 140 lipid-associated genetic variants to estimate associations between circulating HDL cholesterol (HDL-C), LDL cholesterol (LDL-C), and triglycerides and T2D and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics